EUSA's Erwinaze Approval Positions Private Company for Exit
By Trista Morrison
Wednesday, November 23, 2011
EUSA Pharma Inc.'s FDA approval of acute lymphoblastic leukemia (ALL) drug Erwinaze (asparaginase Erwinia chrysanthemi) means the privately held specialty pharma firm may now be poised for an exit.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.